Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques

Vaccine

Volumn 25, Issue 28, 2007, Pages 5220-5231

  Kobinger, Gary P ^a   Figueredo, Joanita M ^b   Rowe, Thomas ^c   Zhi, Yan ^b   Gao, Guangping ^b   Sanmiguel, Julio C ^b   Bell, Peter ^b   Wivel, Nelson A ^b   Zitzow, Lois A ^c   Flieder, Douglas B ^d   Hogan, Robert J ^c   Wilson, James M ^b  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b Laboratory Medicine   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

Adenovirus; SARS; Vaccine

Indexed keywords

ADENOVIRUS VACCINE; ADENOVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; IMMUNE RESPONSE; MALE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, VIRAL; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FERRETS; HUMANS; IMMUNIZATION, SECONDARY; LUNG; MACACA MULATTA; PNEUMONIA; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; T-LYMPHOCYTES; VACCINATION; VIRAL VACCINES;

EID: 34250360726     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.04.065     Document Type: Article

References (30)

1. Li W., Shi Z., Yu M., Ren W., Smith C., Epstein J.H., et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 310 5748 (2005) 676-679
2. Lau S.K., Woo P.C., Li K.S., Huang Y., Tsoi H.W., Wong B.H., et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 102 39 (2005) 14040-14045
3. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., et al. The Genome sequence of the SARS-associated coronavirus. Science 300 5624 (2003) 1399-1404
4. Nicholls J.M., Poon L.L., Lee K.C., Ng W.F., Lai S.T., Leung C.Y., et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 361 9371 (2003) 1773-1778
5. Wong C.K., Lam C.W., Wu A.K., Ip W.K., Lee N.L., Chan I.H., et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 136 1 (2004) 95-103
6. Leroy E.M., Kumulungui B., Pourrut X., Rouquet P., Hassanin A., Yaba P., et al. Fruit bats as reservoirs of Ebola virus. Nature 438 7068 (2005) 575-576
7. Subbarao K., McAuliffe J., Vogel L., Fahle G., Fischer S., Tatti K., et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 78 7 (2004) 3572-3577
8. Hogan R.J., Gao G., Rowe T., Bell P., Flieder D., Paragas J., et al. Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J Virol 78 20 (2004) 11416-11421
9. Fouchier R.A., Kuiken T., Schutten M., van Amerongen G., van Doornum G.J., van den Hoogen B.G., et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423 6937 (2003) 240
10. Rowe T., Gao G., Hogan R.J., Crystal R.G., Voss T.G., Grant R.L., et al. Macaque model for severe acute respiratory syndrome. J Virol 78 20 (2004) 11401-11404
11. McAuliffe J., Vogel L., Roberts A., Fahle G., Fischer S., Shieh W.J., et al. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology 330 1 (2004) 8-15
12. Martina B.E., Haagmans B.L., Kuiken T., Fouchier R.A., Rimmelzwaan G.F., Van Amerongen G., et al. Virology: SARS virus infection of cats and ferrets. Nature 425 6961 (2003) 915
13. ter Meulen J., Bakker A.B., van den Brink E.N., Weverling G.J., Martina B.E., Haagmans B.L., et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363 9427 (2004) 2139-2141
14. Zhi Y., Wilson J.M., and Shen H. SARS vaccine: progress and challenge. Cell Mol Immunol 2 2 (2005) 101-105
15. Taylor D.R. Obstacles and advances in SARS vaccine development. Vaccine (2005)
16. Gao W., Tamin A., Soloff A., D'Aiuto L., Nwanegbo E., Robbins P.D., et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362 9399 (2003) 1895-1896
17. Zhi Y., Kobinger G.P., Jordan H., Suchma K., Weiss S.R., Shen H., et al. Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein. Virology 335 1 (2005) 34-45
18. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170 3 (2003) 1416-1422
19. Kobinger G.P., Feldmann H., Zhi Y., Schumer G., Gao G., Feldmann F., et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology (2005)
20. Gao G., Zhou X., Alvira M.R., Tran P., Marsh J., Lynd K., et al. High throughput creation of recombinant adenovirus vectors by direct cloning, green-white selection and I-Sce I-mediated rescue of circular adenovirus plasmids in 293 cells. Gene Ther 10 22 (2003) 1926-1930
21. Roy S., Gao G., Lu Y., Zhou X., Lock M., Calcedo R., et al. Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum Gene Ther 15 5 (2004) 519-530
22. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 2 (1991) 193-199
23. Gao G.P., Engdahl R.K., and Wilson J.M. A cell line for high-yield production of E1-deleted adenovirus vectors without the emergence of replication-competent virus. Hum Gene Ther 11 1 (2000) 213-219
24. Zitzow L.A., Rowe T., Morken T., Shieh W.J., Zaki S., and Katz J.M. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol 76 9 (2002) 4420-4429
25. Earley E. The lineage of Vero, Vero 76 and its clone C1008 in the United States. In: Simizu B.T.T. (Ed). Vero cell: origin, properties and biomedical applications (1988), Chiba University, Tokyo 26-29
26. Reed L.J., and Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 27 (1938) 493-497
27. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 5514 (2001) 69-74
28. Maher J.A., and DeStefano J. The ferret: an animal model to study influenza virus. Lab Anim (NY) 33 9 (2004) 50-53
29. Weingartl H., Czub M., Czub S., Neufeld J., Marszal P., Gren J., et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 78 22 (2004) 12672-12676
30. Reuman P.D., Keely S., and Schiff G.M. Assessment of signs of influenza illness in the ferret model. J Virol Methods 24 1-2 (1989) 27-34